Genmab Reports $14.35 Billion in DARZALEX® Global Sales for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Globenewswire
- Strong Sales Performance: Genmab announced that global net sales of DARZALEX® (daratumumab) reached $14.35 billion in 2025, with $8.27 billion from the U.S. and $6.09 billion from the rest of the world, indicating robust demand and growth potential for the drug in the global market.
- Royalty Revenue: Genmab's royalties from Johnson & Johnson (J&J) on worldwide net sales reinforce its market position in the antibody drug sector and provide stable funding for future research and development initiatives.
- Market Expansion Potential: With ongoing promotion of DARZALEX® and the development of new indications, Genmab is poised to further increase its market share in the coming years, particularly in the competitive landscape of global cancer treatment.
- Innovation-Driven Growth: Genmab is committed to improving the lives of cancer patients through innovative antibody medicines and will continue to advance its strong clinical pipeline, aiming to deliver transformative therapies and enhance its influence in the biotechnology industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 38.50 USD with a low forecast of 26.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 33.350
Low
26.00
Averages
38.50
High
48.00
Current: 33.350
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alphabet and Nvidia Lead AI Investment Wave, AbbVie and IBKR Show Long-Term Resilience
- AI Investment Opportunity: Alphabet showcases strong cash flow and market leadership with a 34% year-over-year growth in Google Cloud, making it an attractive option for patient investors looking to capitalize on AI technologies.
- Technological Edge: Nvidia revealed at CES 2026 that the revenue potential for its Blackwell and Rubin systems exceeds $500 billion, having secured over half of Taiwan Semiconductor's advanced packaging capacity, indicating robust demand and market dominance in the AI sector.
- Immunology Growth: AbbVie's Skyrizi and Rinvoq achieved year-over-year growth of 46% and 34% in Q3, respectively, with combined sales expected to reach $31 billion by 2027, demonstrating resilience and a diversified strategy post-Humira patent loss.
- Brokerage Business Expansion: Interactive Brokers reported a 21% year-over-year increase in net interest income to $967 million in Q3 2025, with client cash balances hitting $150 billion, reflecting strong performance and market expansion potential in a high-interest rate environment.
Continue Reading
2026 Investment Outlook: Four Stocks with Compounding Potential
- Google Cloud Growth: Alphabet's Google Cloud achieved a 34% year-over-year growth in Q3, with revenue reaching $15.2 billion, indicating strong demand for generative AI, which is expected to further drive overall revenue growth and solidify its market position.
- Nvidia Market Dominance: At CES 2026, Nvidia revealed that the revenue potential for its Blackwell and Rubin systems exceeds $500 billion, and it has secured over half of Taiwan Semiconductor's advanced packaging capacity, which is expected to significantly enhance its profitability and market share.
- AbbVie Immunology Growth: AbbVie's Skyrizi and Rinvoq saw year-over-year growth of 46% and 34% in Q3, respectively, with combined sales expected to reach $31 billion by 2027, demonstrating strong market performance after losing Humira's patent exclusivity.
- Interactive Brokers Client Growth: Interactive Brokers reported a 21% year-over-year increase in net interest income to $967 million in Q3 2025, with client cash balances reaching $150 billion and customer count rising to 4 million, showcasing its strong growth potential in a high-interest rate environment.
Continue Reading